Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2026
Reporting Period: Single event date (February 10, 2026)
This filing reports a significant regulatory milestone under Item 8.01 (Other Events). BioCardia, Inc. announced the completion of its Pre-Submission under the Q-Submission program to the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
Regulatory Progress: The company completed a Pre-Submission to the FDA for its Helix Transendocardial Delivery Catheter. This device is intended for intramyocardial therapeutic and diagnostic agent delivery. This represents a material step in the regulatory approval process for the company's product pipeline.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the Pre-Submission completion. No specific financial guidance or forward-looking projections regarding revenue or timelines are included in the text of this 8-K.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 8.01 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific content of the attached press release (Exhibit 99.1) for details on the FDA's response to the Pre-Submission.
- Confirm the timeline for the next regulatory steps following the Pre-Submission completion.
- Review recent 10-Q or 10-K filings for the most current financial position, as this 8-K contains no financial data.
- Monitor for any subsequent filings regarding the FDA's feedback on the Helix Transendocardial Delivery Catheter.